It’s One of the Greatest Success Stories of Molecular Medicine. Genomics Historian Kevin Davies on His Latest Book about Casgevy and Sickle Cell Disease

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comIt was the heady days of the CRISPR revolution and of the gene therapy Casgevy. And when longtime genomics editor and author Kevin Davies went looking for a book that told the story of sickle cell disease and could not find one, he was perplexed and then inspired.A few years later, the result is Curved Air, a biography of sickle cell anemia that traces one of the most remarkable arcs in modern biology. Davies begins with Victoria Gray, the first sickle cell patient treated with the CRISPR therapy that became Casgevy. Her transformation leads him backward through more than a century of discovery, from the first description of sickled blood cells to the identification of sickle cell as the first molecular disease. He writes of the extraordinary biology of fetal hemoglobin that made today’s therapy possible.This is also a story about the gap between biology and medicine. Davies explores the neglect and discrimination endured by sickle cell patients and the difficulty of bringing a multimillion dollar therapy to those who need it. With a list price of $2.2 million for Casgevy, there is an enormous challenge of extending this advanced therapy to the millions of patients around the world who are in need.